InterPAD - DETAILS

tamoxifen, 10540-29-1, trans-Tamoxifen, Crisafeno, Diemon, Tamoxifene, Citofen, Istubol, Oncomox, Retaxim, Tamoxen, Valodex, Tamoxifeno, Tamoxifenum, Novaldex, Tamoxifen (Z), Mammaton, Tamoxifene [INN-French], Tamoxifenum [INN-Latin], Tamoxifeno [INN-Spanish], Tamoplex, CCRIS 3275, (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, HSDB 6782, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, EINECS 234-118-0, Tamoxifen (INN), NSC-727681, Tamoxifen (Standard), DTXSID1034187, UNII-094ZI81Y45, CHEBI:41774, 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine, CHEMBL83, ICI-47699, Tamizam, 094ZI81Y45, (2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC), 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine, C26H29NO, DTXCID9014187, EC 234-118-0, Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-, Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-, (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE, (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, TAMOXIFEN [INN], TAMOXIFEN (IARC), TAMOXIFEN [IARC], (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, (z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine, Tamoxifene (INN-French), Tamoxifenum (INN-Latin), Tamoxifen [INN:BAN], Tamoxifeno (INN-Spanish), Ethylamine, N,N-dimethyl-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-, (Z)-, (E/Z)-Tamoxifen, 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine, Tamoxifen (1.0 mg/mL in Methanol), Ethanamine, 2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, [3H]tamoxifen, ETHANAMINE, 2-(4-((1Z)-1,2-DIPHENYL-1-BUTEN-1-YL)PHENOXY)-N,N-DIMETHYL-, Tamoxifen (TN), [3H]-tamoxifen, Tamoplex (TN), SMR000059172, CAS-10540-29-1, TRANS FORM OF TAMOXIFEN, ICI 47699, ,citrate, Z-Tamoxifen, 2-(4-((1Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine, Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-, Tamoxifen, 7, Tocris-0999, 1ya4, Tamoxifen, >=99%, TAMOXIFEN [MI], TAMOXIFEN [HSDB], Prestwick2_000146, Prestwick3_000146, Spectrum5_001417, Spectrum5_002043, TAMOXIFEN [VANDF], UPCMLD-DP027, SCHEMBL4084, TAMOXIFEN [WHO-DD], BIDD:PXR0003, Lopac0_001203, BSPBio_000252, BSPBio_001150, BSPBio_001982, MLS001332535, MLS001332536, BIDD:ER0008, BIDD:GT0009, Tamoxifen, analytical standard, BPBio1_000278, GTPL1016, GTPL5384, BDBM20607, cid_2733526, L02BA01, cMAP_000044, HMS1362J11, HMS1792J11, HMS1990J11, HMS2090N08, HMS2232C12, HMS3261D09, HMS3403J11, HMS3411P04, HY-13757AR, ICI47699, Tox21_201243, Tox21_300539, Tox21_500494, (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine, 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene, HB0601, HY-13757A, MFCD00010454, NSC727681, AKOS022143035, AM84324, CCG-205277, DB00675, FD12063, KS-1472, LP00494, SDCCGSBI-0051170.P007, ICI47699;Z-Tamoxifen;trans-Tamoxifen, IDI1_000258, IDI1_002170, QTL1_000079, NCGC00024928-01, NCGC00024928-03, NCGC00024928-04, NCGC00024928-05, NCGC00024928-07, NCGC00024928-08, NCGC00024928-09, NCGC00024928-10, NCGC00024928-11, NCGC00024928-12, NCGC00024928-13, NCGC00024928-14, NCGC00024928-15, NCGC00024928-16, NCGC00024928-17, NCGC00024928-18, NCGC00024928-19, NCGC00024928-39, NCGC00024928-40, NCGC00254455-01, NCGC00258795-01, NCGC00261179-01, AC-35768, BT164438, SBI-0051170.P004, CS-0694848, NS00010353, C07108, D08559, AB00053547-16, AB00053547-17, AB00053547-18, AB00053547_19, AB00053547_20, EN300-1273241, A801229, L024126, Q412178, W-108788, BRD-K93754473-001-02-9, BRD-K93754473-048-04-6, BRD-K93754473-048-05-3, BRD-K93754473-048-10-3, Tamoxifen, certified reference material, TraceCERT(R), Z2527624834, 1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene, (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)phenoxy)-N,N-dimethylethanamine, (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine, (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine, 2-[4-[(Z)-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine

No.	Title	Href
1	In vitro and in vivo effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen. J Pharmacol Sci. 2014;125(4):375-85. doi: 10.1254/jphs.14024fp.	`Click`
2	Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro. Am J Surg. 2010 Nov;200(5):577-80. doi: 10.1016/j.amjsurg.2010.07.022.	`Click`
3	Synergy of Pancratistatin and Tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biol Ther. 2008 Mar;7(3):376-84. doi: 10.4161/cbt.7.3.5364.	`Click`
4	Sensitization of human melanoma cells by tamoxifen to apoptosis induction by pancratistatin, a nongenotoxic natural compound. Melanoma Res. 2011 Feb;21(1):1-11. doi: 10.1097/CMR.0b013e328337abff.	`Click`
5	Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. Mol Ther Oncolytics. 2022 Jan 3;24:340-354. doi: 10.1016/j.omto.2021.12.025.	`Click`
6	Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat. 2009 Nov;118(1):33-43. doi: 10.1007/s10549-008-0216-x.	`Click`
7	The Combinatory Effects of Glabridin and Tamoxifen on Ishikawa and MCF-7 Cell Lines. Nat Prod Commun. 2015 Sep;10(9):1573-6.	`Click`
8	Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells. Cell Biol Int. 2024 Jan 15. doi: 10.1002/cbin.12123.	`Click`
9	Evening Primrose Oil Enhances Tamoxifen's Anticancer Activity against Breast Cancer Cells by Inducing Apoptosis, Inhibiting Angiogenesis, and Arresting the Cell Cycle. Molecules. 2022 Apr 7;27(8):2391. doi: 10.3390/molecules27082391	`Click`
10	Celastrol enhances tamoxifen sensitivity in the treatment of triple negative breast cancer via mitochondria mediated apoptosis pathway. Am J Transl Res. 2023 Apr 15;15(4):2703-2715.	`Click`
11	The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells. J Immunol Res. 2021 Jul 22;2021:5532269. doi: 10.1155/2021/5532269.	`Click`
12	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. Biomed Pharmacother. 2017 May;89:827-837. doi: 10.1016/j.biopha.2017.01.084.	`Click`
13	Enhancing Tamoxifen Therapy with α-Mangostin: Synergistic Antiproliferative Effects on Breast Cancer Cells and Potential Reduced Endometrial Impact. Pharmaceuticals (Basel). 2023 Nov 8;16(11):1576. doi: 10.3390/ph16111576.	`Click`
14	Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem. 2013 Nov 15;141(2):1553-61. doi: 10.1016/j.foodchem.2013.04.077.	`Click`

No.

Title

Href

In vitro and in vivo effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen. J Pharmacol Sci. 2014;125(4):375-85. doi: 10.1254/jphs.14024fp.

Click

Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro. Am J Surg. 2010 Nov;200(5):577-80. doi: 10.1016/j.amjsurg.2010.07.022.

Click

Synergy of Pancratistatin and Tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biol Ther. 2008 Mar;7(3):376-84. doi: 10.4161/cbt.7.3.5364.

Click

Sensitization of human melanoma cells by tamoxifen to apoptosis induction by pancratistatin, a nongenotoxic natural compound. Melanoma Res. 2011 Feb;21(1):1-11. doi: 10.1097/CMR.0b013e328337abff.

Click

Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. Mol Ther Oncolytics. 2022 Jan 3;24:340-354. doi: 10.1016/j.omto.2021.12.025.

Click

Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat. 2009 Nov;118(1):33-43. doi: 10.1007/s10549-008-0216-x.

Click

The Combinatory Effects of Glabridin and Tamoxifen on Ishikawa and MCF-7 Cell Lines. Nat Prod Commun. 2015 Sep;10(9):1573-6.

Click

Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells. Cell Biol Int. 2024 Jan 15. doi: 10.1002/cbin.12123.

Click

Evening Primrose Oil Enhances Tamoxifen's Anticancer Activity against Breast Cancer Cells by Inducing Apoptosis, Inhibiting Angiogenesis, and Arresting the Cell Cycle. Molecules. 2022 Apr 7;27(8):2391. doi: 10.3390/molecules27082391

Click

Celastrol enhances tamoxifen sensitivity in the treatment of triple negative breast cancer via mitochondria mediated apoptosis pathway. Am J Transl Res. 2023 Apr 15;15(4):2703-2715.

Click

The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells. J Immunol Res. 2021 Jul 22;2021:5532269. doi: 10.1155/2021/5532269.

Click

Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. Biomed Pharmacother. 2017 May;89:827-837. doi: 10.1016/j.biopha.2017.01.084.

Click

Enhancing Tamoxifen Therapy with α-Mangostin: Synergistic Antiproliferative Effects on Breast Cancer Cells and Potential Reduced Endometrial Impact. Pharmaceuticals (Basel). 2023 Nov 8;16(11):1576. doi: 10.3390/ph16111576.

Click

Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem. 2013 Nov 15;141(2):1553-61. doi: 10.1016/j.foodchem.2013.04.077.

Click

Name	Tamoxifen
PubChem CID	2733526
Molecular Weight	371.5g/mol
Synonyms	tamoxifen, 10540-29-1, trans-Tamoxifen, Crisafeno, Diemon, Tamoxifene, Citofen, Istubol, Oncomox, Retaxim, Tamoxen, Valodex, Tamoxifeno, Tamoxifenum, Novaldex, Tamoxifen (Z), Mammaton, Tamoxifene [INN-French], Tamoxifenum [INN-Latin], Tamoxifeno [INN-Spanish], Tamoplex, CCRIS 3275, (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, HSDB 6782, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, EINECS 234-118-0, Tamoxifen (INN), NSC-727681, Tamoxifen (Standard), DTXSID1034187, UNII-094ZI81Y45, CHEBI:41774, 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine, CHEMBL83, ICI-47699, Tamizam, 094ZI81Y45, (2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC), 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine, C26H29NO, DTXCID9014187, EC 234-118-0, Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-, Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-, (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE, (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, TAMOXIFEN [INN], TAMOXIFEN (IARC), TAMOXIFEN [IARC], (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, (z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine, Tamoxifene (INN-French), Tamoxifenum (INN-Latin), Tamoxifen [INN:BAN], Tamoxifeno (INN-Spanish), Ethylamine, N,N-dimethyl-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-, (Z)-, (E/Z)-Tamoxifen, 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine, Tamoxifen (1.0 mg/mL in Methanol), Ethanamine, 2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, [3H]tamoxifen, ETHANAMINE, 2-(4-((1Z)-1,2-DIPHENYL-1-BUTEN-1-YL)PHENOXY)-N,N-DIMETHYL-, Tamoxifen (TN), [3H]-tamoxifen, Tamoplex (TN), SMR000059172, CAS-10540-29-1, TRANS FORM OF TAMOXIFEN, ICI 47699, ,citrate, Z-Tamoxifen, 2-(4-((1Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine, Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-, Tamoxifen, 7, Tocris-0999, 1ya4, Tamoxifen, >=99%, TAMOXIFEN [MI], TAMOXIFEN [HSDB], Prestwick2_000146, Prestwick3_000146, Spectrum5_001417, Spectrum5_002043, TAMOXIFEN [VANDF], UPCMLD-DP027, SCHEMBL4084, TAMOXIFEN [WHO-DD], BIDD:PXR0003, Lopac0_001203, BSPBio_000252, BSPBio_001150, BSPBio_001982, MLS001332535, MLS001332536, BIDD:ER0008, BIDD:GT0009, Tamoxifen, analytical standard, BPBio1_000278, GTPL1016, GTPL5384, BDBM20607, cid_2733526, L02BA01, cMAP_000044, HMS1362J11, HMS1792J11, HMS1990J11, HMS2090N08, HMS2232C12, HMS3261D09, HMS3403J11, HMS3411P04, HY-13757AR, ICI47699, Tox21_201243, Tox21_300539, Tox21_500494, (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine, 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene, HB0601, HY-13757A, MFCD00010454, NSC727681, AKOS022143035, AM84324, CCG-205277, DB00675, FD12063, KS-1472, LP00494, SDCCGSBI-0051170.P007, ICI47699;Z-Tamoxifen;trans-Tamoxifen, IDI1_000258, IDI1_002170, QTL1_000079, NCGC00024928-01, NCGC00024928-03, NCGC00024928-04, NCGC00024928-05, NCGC00024928-07, NCGC00024928-08, NCGC00024928-09, NCGC00024928-10, NCGC00024928-11, NCGC00024928-12, NCGC00024928-13, NCGC00024928-14, NCGC00024928-15, NCGC00024928-16, NCGC00024928-17, NCGC00024928-18, NCGC00024928-19, NCGC00024928-39, NCGC00024928-40, NCGC00254455-01, NCGC00258795-01, NCGC00261179-01, AC-35768, BT164438, SBI-0051170.P004, CS-0694848, NS00010353, C07108, D08559, AB00053547-16, AB00053547-17, AB00053547-18, AB00053547_19, AB00053547_20, EN300-1273241, A801229, L024126, Q412178, W-108788, BRD-K93754473-001-02-9, BRD-K93754473-048-04-6, BRD-K93754473-048-05-3, BRD-K93754473-048-10-3, Tamoxifen, certified reference material, TraceCERT(R), Z2527624834, 1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene, (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)phenoxy)-N,N-dimethylethanamine, (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine, (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine, 2-[4-[(Z)-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine
Drug Type	Small molecule
Formula	C₂₆H₂₉NO
SMILES	CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
InChI	1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChIKey	NKANXQFJJICGDU-QPLCGJKRSA-N
CAS Number	10540-29-1
ChEMBL ID	CHEMBL83
ChEBI ID	CHEBI:41774
TTD ID	D07KSG
Drug Bank ID	DB00675
KEGG ID	C07108
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Xanthorrhizol, Tamoxifen
Partner Name	Xanthorrhizol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	MAPK14	hsa1432
Gene Regulation	Up-regulation	Expression	PSMD9	hsa5715
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vivo Model	Using the MCF-7 implanted nude mice model, it was possible to detect significantly increased tumor volumes, a larger tumor size, and increased protein expression of P38 and P27(Kip1) in the xanthorrhizol + tamoxifen group compared to the tamoxifen-alone group.
Result	It can be concluded that while there is no significant herb-drug interaction between xanthorrhizol and tamoxifen in vitro, there is such an interaction in tumor-bearing mice, which provides important information that affects breast cancer treatment translational research.

Pair Name	Pterostilbene, Tamoxifen
Partner Name	Pterostilbene
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	ZR-75-1	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0588
Result	Pterostilbene shows an additive inhibitory effect on breast cancer cells when combined with tamoxifen, most likely from augmented cancer cell apoptosis.

Pair Name	Pancratistatin, Tamoxifen
Partner Name	Pancratistatin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Mitochondria-mediated apoptosis
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	In combination with the anti-estrogen Tamoxifen, PST had a synergic effect

Pair Name	Pancratistatin, Tamoxifen
Partner Name	Pancratistatin
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
Result	Our results indicate that TAM alone does not induce apoptosis in this cell line, but sensitizes the mitochondria, thereby enhancing the effect of PST exposure. In conclusion, combination of two nongenotoxic compounds offers a novel treatment regime for this notoriously resilient form of skin cancer.

Pair Name	Narciclasine, Tamoxifen
Partner Name	Narciclasine
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Target-->STAT3
Gene Regulation	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Phosphorylation	STAT3	hsa6774
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Our findings successfully highlight the STAT3 as the direct therapeutic target of Nar in ER-positive breast cancer cells, especially, Nar leaded STAT3 degradation as a promising strategy for the tamoxifen-resistant breast cancer treatment.

Pair Name	Methylselenocysteine, Tamoxifen
Partner Name	Methylselenocysteine
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	CCND1	hsa595
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vivo Model	About 5×10⁶ cells suspension in 50 uL sterile PBS were mixed with 100 uL Matrigel and administered within both sides of the inguinal mammary fat pad of NU/NU immune-compromised female ovariectomized mice
Result	These findings demonstrate synergistic growth inhibition of ERalpha positive breast cancer xenografts by combination of tamoxifen with organic selenium compounds. Organic selenium may provide added benefit when combined with tamoxifen in adjuvant therapy or prevention.

Pair Name	Glabridin, Tamoxifen
Partner Name	Glabridin
Disease Info	[ICD-11: 2C76]	Endometrial cancer		Investigative
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
Gene Regulation	Up-regulation	Expression	ESR1	hsa2099
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	Ishikawa	Endometrial adenocarcinoma	Homo sapiens (Human)	CVCL_2529
Result	These results suggested that the combination of tamoxifen and glabridin has potential to be used as an estrogen replacement drug with a reduced risk of endometrial cancer that has arisen from the intake of tamoxifen.

Pair Name	Ginsenoside Rg3, Tamoxifen
Partner Name	Ginsenoside Rg3
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Inhibition-->Glycolysis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PFKFB3	hsa5209
	Down-regulation	Expression	PFKM	hsa5213
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	T-47D	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0553
	HEK293T	Healthy	Homo sapiens (Human)	CVCL_0063
In Vivo Model	A total of 6×10⁶ cells were suspended in 100 μL of a 1:1 mixture of Matrigel and phosphate-buffered saline (PBS),and then injected into the flanks of nude mice.
Result	This study highlights the contribution of Rg3 in enhancing the therapeutic efficacy of TAM in breast cancer, and suggests that targeting TAM-resistant PFKFB3 overexpression may represent a promising strategy to improve the response to combination therapy in breast cancer.

Pair Name	Evening primrose oil, Tamoxifen
Partner Name	Evening primrose oil
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Inhibition-->Tumor angiogenesis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	The most significant finding of this study was the confirmation of the anticancer activity of the natural product EPO, which potentiated the activity of the anticancer drug TAM against MCF-7 and MDA-MB-231 BC cell lines through the induction of apoptosis, inhibiting angiogenesis and halting cell proliferation.

Pair Name	Celastrol, Tamoxifen
Partner Name	Celastrol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Mitochondria-mediated apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	CYCS	hsa54205
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vivo Model	The cell concentration was adjusted to 4×10⁷ pieces/mL. The single cell suspension was injected under the fourth pair of breast pads on the right side of nude mice, 0.1 mL for each.
Result	CEL can promote apoptosis and enhance the TAM sensitivity in TNBC treatment through a mitochondria-mediated pathway.

Pair Name	Carnosic acid, Tamoxifen
Partner Name	Carnosic acid
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAD	hsa572
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP8	hsa841
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Expression	TNFRSF10C	hsa8794
	Up-regulation	Expression	TNFRSF10D	hsa8793
	Up-regulation	Expression	TNFSF10	hsa8743
	Up-regulation	Expression	TP53	hsa7157
	Up-regulation	Expression	TP73	hsa7161
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	T-47D	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0553
In Vivo Model	5×10⁵ MCF-7 cells were subcutaneously injected into the dorsal flanks of athymic nude mice.
Result	Our study supplies a novel therapeutic strategy to induce apoptosis for suppressing breast cancer, which was relied on Caspase-3/TRAIL activation.

Pair Name	Alpha-Mangostin, Tamoxifen
Partner Name	Alpha-Mangostin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	KCNH1	hsa3756
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	T-47D	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0553
	Royan N30	Healthy	Mus musculus (Mouse)	CVCL_9414
Result	This study establishes the benefits of incorporating AM as a co-adjuvant for first-line ER+ breast cancer therapy.

Pair Name	Luteolin, Tamoxifen
Partner Name	Luteolin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Down-regulation	Expression	CCNE2	hsa9134
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	BT-483	Invasive breast carcinoma	Homo sapiens (Human)	CVCL_2319
	BT-474	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0179
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	AU565	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_1074
	MCF-10A	Healthy	Homo sapiens (Human)	CVCL_0598
Result	The results of this study suggest that luteolin can be used as a chemosensitiser to target the expression level of CCNE2 and that it could be a novel strategy to overcome TAM resistance in breast cancer patients.